We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 694

Swearing Behind A Reference With Reasonably Continuous Diligence
  • Foley & Lardner LLP
  • USA
  • November 16 2016

In Perfect Surgical Techniques, Inc. v. Olympus America, Inc., the Federal Circuit vacated and remanded a USPTO Patent Trial and Appeal Board


District Court Denies Extra Patent Term Adjustment When National Stage Entry Date Falls On A Holiday
  • Foley & Lardner LLP
  • USA
  • October 27 2016

Some patent term adjustment (PTA) cases have broad impact-like Wyeth v. Kappos and Novartis v. Lee-but Acetelion Pharmaceuticals, Inc. v. Lee


The Decision To Grant Rehearing En Banc In Apple v. Samsung
  • Foley & Lardner LLP
  • USA
  • October 25 2016

On October 7, 2016, the Federal Circuit issued another decision in the ongoing patent litigations between Apple and Samsung that began in the Northern


PTAB Upholds Lialda Patent Over Kyle Bass IPR Challenge
  • Foley & Lardner LLP
  • USA
  • October 11 2016

The USPTO Patent Trial and Appeal Board (PTAB) has issued a Final Written Decision upholding Shire’s Lialda patent over the Inter Partes Review


The New Supreme Court Term: Cases for the Automotive Industry to Watch
  • Foley & Lardner LLP
  • USA
  • October 10 2016

A new Supreme Court term is once again underway. This one looks to be unique in that it is likely to be an eight-Justice bench into 2017with


Judge Grants Gilead Motion To Invalidate Remicade Patent For Obviousness-Type Double Patenting
  • Foley & Lardner LLP
  • USA
  • October 5 2016

The FDA approved Inflectra-Celltrion’s biosimilar version of Janssen’s Remicade (infliximab) product-in April 2016, but according to Pfizer’s press


Federal Circuit Finds Claims Implemented on a General Purpose Cellphone Not Patentable
  • Foley & Lardner LLP
  • USA
  • October 3 2016

In Alice Corp. v. CLS Bank International, the Supreme Court applied its two-part test for patent eligibility under 35 U.S.C. 101 - i.e., (1


Inherent Disclosure Supports Priority Claim
  • Foley & Lardner LLP
  • USA
  • September 28 2016

In Yeda Research and Development Co. v. Abbott GmbH and Co., the Federal Circuit invoked the doctrine of inherent disclosure to uphold a priority


Inherent Disclosure Satisfied Written Description
  • Foley & Lardner LLP
  • USA
  • September 21 2016

In Yeda Research and Development Co., Ltd. v. Abbott GMBH & Co. KG, Slip Op. 2015-1662 (Fed. Cir. 2016), the Federal Circuit held that a claim to an


CAFC Says Functional Claim Language Does Not Create Divided Infringement
  • Foley & Lardner LLP
  • USA
  • September 20 2016

In LifeNet Health v. LifeCell Corporation, one of the many issues the Federal Circuit decided was that functional claim language did not create a